Naoki Takezako

4.2k total citations · 1 hit paper
104 papers, 1.8k citations indexed

About

Naoki Takezako is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Naoki Takezako has authored 104 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Hematology, 43 papers in Oncology and 37 papers in Molecular Biology. Recurrent topics in Naoki Takezako's work include Multiple Myeloma Research and Treatments (57 papers), Protein Degradation and Inhibitors (22 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Naoki Takezako is often cited by papers focused on Multiple Myeloma Research and Treatments (57 papers), Protein Degradation and Inhibitors (22 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Naoki Takezako collaborates with scholars based in Japan, United States and France. Naoki Takezako's co-authors include Meletios Α. Dimopoulos, Philippe Moreau, Jesús F. San Miguel, Akiyoshi Miwa, Kenshi Suzuki, Atsushi Togawa, Rie Yamamoto, Miyuki Suguro, Yoshinobu Kanda and Tamae Hamaki and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Naoki Takezako

98 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

2018 364 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →

Peers

Naoki Takezako

HEMAT

ONCOL

IMMUN

GENET

Sunil Abhyankar United States

Sang Kyun Sohn South Korea

Christine Wolschke Germany

Cecilie Blimark Sweden

Edward Kanfer United Kingdom

Alida Dominietto Italy

Mar Tormo Spain

Makoto Onizuka Japan

Masamitsu Yanada Japan

Nathalie Contentin France

Sunil Abhyankar United States

Naoki Takezako

1.2k ×1.0

HEMAT

482 ×0.6

ONCOL

452 ×0.6

552 ×1.6

IMMUN

345 ×1.1

GENET

Citations per year, relative to Naoki Takezako Naoki Takezako (= 1×) peers Sunil Abhyankar

Countries citing papers authored by Naoki Takezako

Since Specialization

Citations

This map shows the geographic impact of Naoki Takezako's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Takezako with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Takezako more than expected).

Fields of papers citing papers by Naoki Takezako

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Takezako. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Takezako. The network helps show where Naoki Takezako may publish in the future.

Co-authorship network of co-authors of Naoki Takezako

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Takezako. A scholar is included among the top collaborators of Naoki Takezako based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Takezako. Naoki Takezako is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mori, Yasuo, Jun Takizawa, Naoki Takezako, et al.. (2024). Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer Science. 115(6). 2002–2011. 1 indexed citations

Takezako, Naoki, et al.. (2023). Eight‐color multiparameter flow cytometry (EuroFlow‐NGF) is as sensitive as next‐generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. SHILAP Revista de lepidopterología. 4(1). 184–191. 3 indexed citations

Wada, Hideo, Kazuo Kawasugi, Goichi Honda, et al.. (2023). Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin. SHILAP Revista de lepidopterología. 7(1). e65–e75. 2 indexed citations

Madoiwa, Seiji, Goichi Honda, Noriaki Kawano, et al.. (2021). An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection. International Journal of Laboratory Hematology. 43(6). 1566–1574. 3 indexed citations

Takamatsu, Hiroyuki, Naoki Takezako, Takeshi Yamashita, et al.. (2020). Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs. Next-Generation Sequencing. Blood. 136(Supplement 1). 22–23. 2 indexed citations

Dimopoulos, Meletios Α., Philippe Moreau, Shinsuke Iida, et al.. (2019). Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. International Journal of Hematology. 110(4). 466–473. 7 indexed citations

Ozaki, Shuji, Hiroshi Handa, Takayuki Saitoh, et al.. (2019). Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of Hematology. 98(7). 1703–1711. 9 indexed citations

Sugiura, Isamu, Kenshi Suzuki, Masaki Ri, et al.. (2019). Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. International Journal of Hematology. 111(1). 57–64. 1 indexed citations

Najima, Yuho, Chikashi Yoshida, Noriyoshi Iriyama, et al.. (2018). Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. Leukemia Research. 66. 66–72. 29 indexed citations

10.

Sekiguchi, Naohiro, Tomoko Kitagawa, Ken‐ichi Ito, et al.. (2018). Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. Blood Research. 53(2). 117–117. 4 indexed citations

11.

Takezako, Naoki, Kensuke Ohta, Hiroshi Handa, et al.. (2017). Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan. Blood. 130. 434–434. 3 indexed citations

12.

Nagata, Akihisa, et al.. (2015). Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patients. International Journal of Hematology. 101(3). 268–272. 4 indexed citations

13.

Takezako, Naoki, Naohiro Sekiguchi, Akira Tanimura, et al.. (2013). Lymphocytosis in Idiopathic Thrombocytopenic Purpura Patients Infected by <i>Helicobacter pylori</i>. 3(1). 32–35. 3 indexed citations

14.

Sekiguchi, Naohiro, et al.. (2011). [Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].. PubMed. 52(2). 87–9. 1 indexed citations

15.

Yonemori, Kan, Naoki Takezako, Kazuko Nishimura, et al.. (2002). Fungal Infection in Neutropenic Patients in a Hospital during Construction. Japanese Journal of Infectious Diseases. 55(4). 126–127. 10 indexed citations

16.

Yonemori, Kan, Yoshinobu Kanda, Rie Yamamoto, et al.. (2001). Clinical Value of Serial Measurement of Serum C-Reactive Protein Level in Neutropenic Patients. Leukemia & lymphoma. 41(5-6). 607–614. 12 indexed citations

17.

Suguro, Miyuki, Rie Yamamoto, Aki Chizuka, et al.. (2000). High serum lactate dehydrogenase level predicts short survival after vincristine–doxorubicin–dexamethasone (VAD) salvage for refractory multiple myeloma. American Journal of Hematology. 65(2). 132–135. 1 indexed citations

18.

Suguro, Miyuki, Rie Yamamoto, Aki Chizuka, et al.. (2000). High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. American Journal of Hematology. 65(2). 132–135. 12 indexed citations

19.

Kanda, Yoshinobu, Tamae Hamaki, Rie Yamamoto, et al.. (2000). The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia. Cancer. 88(11). 2529–2533. 34 indexed citations

20.

Kanda, Yoshinobu, Rie Yamamoto, Aki Chizuka, et al.. (2000). Treatment of Deep Vein Thrombosis Using Temporary Vena Caval Filters after Allogeneic Bone Marrow Transplantation. Leukemia & lymphoma. 38(3-4). 429–433. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact